BW
PEARW

Boaz Weinstein’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Boaz Weinstein’s Portfolio PEARW Stock Details PEARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-211,664
Closed -$201K – 507
2021
Q1 		$201K Buy
+211,664
New +$206K 0.01% 370

Other funds holding PEARW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $244M AUM 110.95% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

Boaz Weinstein's PEARW Position: Q2 2021 in Review

Boaz Weinstein sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2021, closing a stake of 211,664 shares — an estimated $201K sold.

Boaz Weinstein first reported a position in PEARW in Q1 2021 and held it in 1 quarter. The position peaked at $201K in Q1 2021. 45 funds tracked by Wall St. Rank hold PEARW as of Q2 2021.

  • Boaz Weinstein reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Boaz Weinstein sold 211,664 Pear Therapeutics, Inc. Warrant shares in Q2 2021, an estimated $201K.
  • Boaz Weinstein first reported a position in Pear Therapeutics, Inc. Warrant in Q1 2021 and held it in 1 quarter.
  • Boaz Weinstein's Pear Therapeutics, Inc. Warrant position peaked at $201K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2021.

Based on Saba Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.